Evoke Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

Evoke Pharma

08/11/2024 21:07

* Evoke Pharma Inc  EVOK.OQ  reported a quarterly adjusted
loss
of 94 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-6.12.  The lone analyst forecast for the
quarter was for a loss of 38 cents per share. 
    * Revenue rose 69.8% to $2.65 million from a year ago;
analysts
expected $3.36 million. 
    * Evoke Pharma Inc's reported EPS for the quarter was a loss
of 94
cents​.
    * The company reported a quarterly loss of $1.31 million.
    * Evoke Pharma Inc shares had risen by 18.8% this
quarter and
lost 55.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 416.7% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Evoke Pharma Inc
is 18.00 
This summary was machine generated from LSEG data November 8 at
09:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.38          -0.94          Missed
 Jun. 30 2024      -0.72          -0.93          Missed
 Mar. 31 2024      -2.52          -2.04          Beat
 Dec. 31 2023      -6.00          -7.08          Missed